Previous close | 66.88 |
Open | 67.18 |
Bid | 69.11 x 500 |
Ask | 69.42 x 500 |
Day's range | 67.18 - 71.62 |
52-week range | 56.05 - 100.77 |
Volume | |
Avg. volume | 1,958,388 |
Market cap | 12.537B |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 89.91 |
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MADISON, Wis., March 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing
MADISON, Wis., March 27, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world.